Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Roderick de Bruijn"'
Autor:
Umberto Capitanio, Börje Ljungberg, Avi Raman, B.W. Lagerveld, Joost M. Blok, Roderick de Bruijn, Kees Hendricksen, Patricia J. Zondervan, Axel Bex, Andrea Minervini, Simon Horenblas, Niels M. Graafland, Teele Kuusk, Barak Rosenzweig
Publikováno v:
Urologic oncology, 38(5), 521-525. Elsevier Inc.
Introduction and Objective Adjuvant studies with checkpoint inhibitors have attracted new interest in accurate pathological lymph node (LN) staging in renal cell carcinoma. Sentinel lymph node (SN) studies in cN0 patients revealed the pattern of lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5133aacd2ee1ccc601009277ce94f0
https://doi.org/10.1016/j.urolonc.2019.12.023
https://doi.org/10.1016/j.urolonc.2019.12.023
Autor:
Igle J. de Jong, Christian U. Blank, Thomas Powles, Roland Van Velthoven, Maureen J.B. Aarts, Michael A.S. Jewett, Sandrine Marreaud, Sandra Collette, Lori Wood, Sylvie Rottey, Harm H.E. van Melick, Peter F.A. Mulders, John B. A. G. Haanen, Axel Bex, Johannes V. Van Thienen, Jean Baptiste Lattouf, Bertrand Tombal, John Wagstaff, Laurence Collette, Roderick de Bruijn
Publikováno v:
European Urology, Vol. 76, no. 4, p. 437-440 (2019)
European Urology, 76, 437-440
European Urology, 76(4), 437-440. ELSEVIER SCIENCE BV
European Urology, 76(4), 437-440. Elsevier
European Urology, 76, 4, pp. 437-440
European Urology, 76, 437-440
European Urology, 76(4), 437-440. ELSEVIER SCIENCE BV
European Urology, 76(4), 437-440. Elsevier
European Urology, 76, 4, pp. 437-440
The European Organisation for Research and Treatment of Cancer SURTIME trial explored timing of sunitinib, a tyrosine kinase inhibitor (TKI), and cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. Previous retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0e7e8b92600ad6a6b0194b11b05123
https://doi.org/10.1016/j.eururo.2019.06.006
https://doi.org/10.1016/j.eururo.2019.06.006
Autor:
Christian U. Blank, Axel Bex, Roderick de Bruijn, John B. A. G. Haanen, Simon Horenblas, Teele Kuusk, Allard Noe, Kees Hendricksen
Publikováno v:
Urology, 109, 127-132. Elsevier Inc.
de Bruijn, R E, Kuusk, T, Noe, A P, Blank, C U, Haanen, J B A G, Hendricksen, K, Horenblas, S & Bex, A 2017, ' Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma ', Urology, vol. 109, pp. 127-132 . https://doi.org/10.1016/j.urology.2017.06.048
de Bruijn, R E, Kuusk, T, Noe, A P, Blank, C U, Haanen, J B A G, Hendricksen, K, Horenblas, S & Bex, A 2017, ' Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma ', Urology, vol. 109, pp. 127-132 . https://doi.org/10.1016/j.urology.2017.06.048
Objective To determine the time-to-targeted therapy (TTT) in patients with not completely resected low-volume oligometastatic disease who were observed following debulking cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6c3b5a21f56ecbf13034ba2002a2d8
https://doi.org/10.1016/j.urology.2017.06.048
https://doi.org/10.1016/j.urology.2017.06.048
Autor:
Christian U. Blank, Roderick de Bruijn, Akhila Wimalasingham, Sarah J. Welsh, Michael Staehler, Teele Kuusk, Bernadett Szabados, John B. A. G. Haanen, Thomas Powles, Tobias Klatte, Grant D. Stewart, Axel Bex
Publikováno v:
European urology oncology. 3(2)
Background Cancer du Rein Metastatique Nephrectomie et Antiangiogeniques (CARMENA) concluded that sunitinib alone is not inferior to cytoreductive nephrectomy (CN) followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors (VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defc1b92e8147cc5881e44e6a8c96156
https://pubmed.ncbi.nlm.nih.gov/32201134
https://pubmed.ncbi.nlm.nih.gov/32201134
Autor:
Maarten L. Donswijk, Henk G. van der Poel, Warner Prevoo, Roderick de Bruijn, Teele Kuusk, Renato A. Valdés Olmos, Axel Bex, Simon Horenblas, Kees Hendricksen, Oscar R. Brouwer, Katarzyna Jóźwiak, Esther Wit, Bas W.G. van Rhijn
Publikováno v:
EJNMMI Research
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
Background Sentinel lymph node biopsy (SLNB) after intratumoral injection of 99mTc labeled nanocolloid and imaging with scintigraphy and SPECT/CT in renal tumors is feasible. However, sentinel lymph node (SN) non-detection rate with scintigraphy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54cbb656f3bf7c52d5ce9c1ebcba4f62
https://pubmed.ncbi.nlm.nih.gov/30511175
https://pubmed.ncbi.nlm.nih.gov/30511175
Autor:
Bas W.G. van Rhijn, Teele Kuusk, Axel Bex, Esther Wit, Maarten L. Donswijk, Nikolaos Grivas, Roderick de Bruijn, Henk G. van der Poel, Jeroen de Jong, Kees Hendricksen, Oscar R. Brouwer, Warner Prevoo, Renato A. Valdés Olmos, Simon Horenblas
Publikováno v:
The Journal of Urology, 199(6), 1426-1432. Elsevier Inc.
Kuusk, T, De Bruijn, R, Brouwer, O R, De Jong, J, Donswijk, M, Grivas, N, Hendricksen, K, Horenblas, S, Prevoo, W, Valdés Olmos, R A, Van Der Poel, H G, Van Rhijn, B W, Wit, E M & Bex, A 2018, ' Lymphatic drainage from renal tumors in vivo : a prospective sentinel node study using SPECT/CT imaging ', The Journal of Urology, vol. 199, no. 6, pp. 1426-1432 . https://doi.org/10.1016/j.juro.2017.11.112
Kuusk, T, De Bruijn, R, Brouwer, O R, De Jong, J, Donswijk, M, Grivas, N, Hendricksen, K, Horenblas, S, Prevoo, W, Valdés Olmos, R A, Van Der Poel, H G, Van Rhijn, B W, Wit, E M & Bex, A 2018, ' Lymphatic drainage from renal tumors in vivo : a prospective sentinel node study using SPECT/CT imaging ', The Journal of Urology, vol. 199, no. 6, pp. 1426-1432 . https://doi.org/10.1016/j.juro.2017.11.112
PURPOSE: Lymphatic drainage from renal tumors is unpredictable and in vivo drainage studies of primary lymphatic landing sites may reveal the variability and dynamics of lymphatic connections. The purpose of this study was to investigate the lymphati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f451687b5f797bd79c4c32e1fffffa2b
https://pubmed.ncbi.nlm.nih.gov/29555540
https://pubmed.ncbi.nlm.nih.gov/29555540
Publikováno v:
MINERVA MEDICA, 108(4), 357-369. Edizioni Minerva Medica S.p.A.
Kuusk, T, Grivas, N, de Bruijn, R & Bex, A 2017, ' The current management of renal cell carcinoma ', MINERVA MEDICA, vol. 108, no. 4, pp. 357-369 . https://doi.org/10.23736/S0026-4806.17.05058-3
Kuusk, T, Grivas, N, de Bruijn, R & Bex, A 2017, ' The current management of renal cell carcinoma ', MINERVA MEDICA, vol. 108, no. 4, pp. 357-369 . https://doi.org/10.23736/S0026-4806.17.05058-3
Although the broad use of ultrasound and computed tomography (CT) has led to an early diagnosis of the disease, renal cell carcinoma (RCC) remains one of the most lethal urological cancers. The present review is based on the latest data published on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eef24c50bb56ac7ec7f222114d509a2
https://research.vumc.nl/en/publications/a62c8695-77b0-48f2-8ebf-00461fcd230b
https://research.vumc.nl/en/publications/a62c8695-77b0-48f2-8ebf-00461fcd230b
Publikováno v:
Urology. 81:111-115
To evaluate the probability of downsizing primary renal tumors by targeted therapy in correlation to size.A literature search was conducted and our own data were pooled with data of retrospective series and prospective trials in which patients were t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ada8f49743e2617e21a030439c2353c
https://doi.org/10.1016/j.urology.2012.09.014
https://doi.org/10.1016/j.urology.2012.09.014
Autor:
Christian U. Blank, Roderick de Bruijn, Simon Horenblas, John B. A. G. Haanen, Axel Bex, Allard Noe
Publikováno v:
World journal of urology. 34(8)
To compare prognostic performance of MSKCC and IMDC risk models in patients with synchronous mRCC. Retrospective analysis of pre-therapeutic MSKCC and IMDC prognostic factors and outcomes in patients with synchronous mRCC treated at a single institut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d98440475be6b5a1e665e987d37019a
https://pubmed.ncbi.nlm.nih.gov/26832350
https://pubmed.ncbi.nlm.nih.gov/26832350
Autor:
Akhila Wimalasingham, Christian U. Blank, Alfonso Gomez De Liano Lista, Thomas Hopkins, Bernadett Szabados, Thomas Powles, Roderick de Bruijn, John B. A. G. Haanen, Peter E Hall, Simon Chowdhury, Axel Bex
Publikováno v:
Journal of Clinical Oncology. 35:514-514
514 Background: The safety and efficacy of upfront VEGF targeted, before nephrectomy in metastatic clear cell renal cancer (mCCRC) has not been robustly evaluated. Methods: In this study we performed a meta-analysis of 3 studies (NCT) with an almost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::085105a3ac2ded20f0a2096ad09b9362
https://doi.org/10.1200/jco.2017.35.6_suppl.514
https://doi.org/10.1200/jco.2017.35.6_suppl.514